|Bid||25.50 x 1100|
|Ask||0.00 x 900|
|Day's Range||25.47 - 26.26|
|52 Week Range||25.47 - 53.17|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||8.73|
|Earnings Date||Apr 29, 2019 - May 3, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.54|
MEDNAX, Inc. (MD), will host an investor conference call and webcast on Thursday, May 2, 2019 at 10:00 a.m. ET, to discuss results from operations for the three months ended March 31, 2019. The investor conference call will be webcast and can be accessed at MEDNAX’s website, www.mednax.com/investors. MEDNAX, Inc. is a national health solutions partner comprised of the nation's leading providers of physician services.
MEDNAX Inc NYSE:MDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for MD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MD are favorable with net inflows of $70.26 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings release MEDNAX, Inc.'s (NYSE:MD) announced in December 2018 showed that the...
CVS Health Corp, Walgreens Boots Alliance Inc., Mednax Inc. and Amdocs Ltd. have declined to their respective three-year lows
MEDNAX, Inc. (MD), today announced its affiliation with Georgia Neonatology, LLC, a private neonatology practice based in Athens, Ga. Georgia Neonatology has provided neonatology services to Piedmont Healthcare’s Piedmont Athens Regional Medical Center location since 2013. The practice specializes in neonatal care for pre-term newborns and critically ill babies.
MEDNAX, Inc. (MD), the national health solutions partner specializing in neonatology, anesthesiology, radiology, maternal-fetal medicine, other pediatric services, and management services, today announced the nomination of Carlos A. Migoya and Michael A. Rucker to stand for election to the Company’s Board of Directors at its Annual Meeting of Shareholders on May 16, 2019. As previously announced, MEDNAX’s Board and its Nominating and Corporate Governance Committee initiated a process, with the support of the nationally-recognized executive search firm Spencer Stuart, to evaluate the Board’s composition and identify additional director candidates to help drive MEDNAX’s strategy.
UBS Group AG (UBS), AutoNation Inc. (AN), Mednax Inc. (MD) and Amdocs Ltd. (DOX) have declined to three-year lows. The price of UBS Group shares declined to $11.88 on March 22, which is only 2.3% above the three-year low of $11.61. UBS is a Swiss investment bank and financial services company.
Announcement: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc. New York, March 22, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the marketRead More...
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
MedData, a MEDNAX (MD) company and a leading provider of technology-enabled management services for hospitals and healthcare providers, today announced the launch of MedData FastTrack, a tech-infused solution for faster reimbursement. “Physicians and physician practices want a faster, less complicated method of medical coding and billing that helps maintain a steady stream of cash in the door,” said MedData President and COO Emily Fisher.
MEDNAX, Inc. (MD), announced today the closing of the previously announced private placement of $500 million aggregate principal amount of its 6.250% senior notes due January 15, 2027 (the “Notes”). The completed transaction resulted in approximately $491.7 million in net proceeds to MEDNAX, which will be used to repay a portion of the indebtedness outstanding under its senior unsecured revolving credit facility. The Notes were offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act.
The Notes were offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act.
MEDNAX, Inc. (MD), announced today that it is proposing to issue $200 million aggregate amount of 6.250% senior notes due 2027 (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be issued as additional notes under an indenture, dated as of December 8, 2015, as supplemented by Supplemental Indenture No. 5 thereto, dated as of November 13, 2018 (collectively, the “Indenture”), pursuant to which the Company previously issued $500 million in aggregate principal amount of its 6.250% senior notes due 2027 (the “Existing Notes”). If the offering is successfully completed, MEDNAX intends to use the net proceeds from the offering to repay a portion of the indebtedness outstanding under its senior unsecured revolving credit facility.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2003 Roger Medel was appointed CEORead More...
Mednax (MD) delivered earnings and revenue surprises of 1.10% and 2.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?